Image credit Weight loss is an incredible journey; if you’ve been through it, you know how frustrating and overwhelmin ...

Originally approved to help with excess weight and obesity, the injectable Wegovy and its sibling-product Ozempic, which is ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Some fear weight-loss stocks are approaching bubble territory, but this incumbent player continues to prove its worth ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

Health officials in England are considering a staggered roll out of an obesity drug due to high levels of demand. Nearly a quarter of a million people are expected to receive the Mounjaro jab over the ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...